Cystic fibrosis papers of the year 2017

被引：2

作者：

Doull, Iolo ^{[1
,2
]}

机构：

[1] Childrens Hosp Wales, Dept Paediat Resp Med, Cardiff CF14 4XN, S Glam, Wales

[2] Childrens Hosp Wales, Paediat Cyst Fibrosis Ctr, Cardiff CF14 4XN, S Glam, Wales

来源：

PAEDIATRIC RESPIRATORY REVIEWS | 2018年 / 27卷

关键词：

Cystic fibrosis; Ivacaftor; Lumacaftor; Tezacaftor; Doxycycline; MRSA; RESISTANT STAPHYLOCOCCUS-AUREUS; PHE508DEL CFTR MUTATION; AGED; 6-11; YEARS; TEZACAFTOR-IVACAFTOR; LUNG-FUNCTION; LUMACAFTOR/IVACAFTOR; EFFICACY; F508DEL-CFTR; COMBINATION; PHASE-3;

D O I：

10.1016/j.prrv.2018.03.001

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

The number of published articles on Cystic Fibrosis (CF) continues to increase year on year. The evidence base for small molecule therapies in CF has continued to expand, with evidence for lumacaftor/ivacaftor in younger patients and longer-term evidence in adults, and pivotal studies on tezacaftor/ivacaftor. There were reports on emerging CFTR mutation agnostic therapies, and new evidence for long standing therapies. (C) 2018 Elsevier Ltd. All rights reserved.

引用

页码：2 / 5

页数：4

共 50 条

[41] CFTR-function and ventilation inhomogeneity in individuals with cystic fibrosis [J].

Bernasconi, Nadine ;

Kieninger, Elisabeth ;

Shaw, Michelle ;

Kurz, Johanna ;

Moeller, Alexander ;

Ratjen, Felix ;

Rochat, Isabelle ;

Stanojevic, Sanja ;

Singer, Florian .

JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (04) :641-647

[42] Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis: A Review of Registry-Based Evidence [J].

Salvatore, Donatello ;

Pepe, Angela .

JOURNAL OF CLINICAL MEDICINE, 2025, 14 (11)

[43] Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype [J].

McGarry, Meghan E. ;

McColley, Susanna A. .

PEDIATRIC PULMONOLOGY, 2021, 56 (06) :1496-1503

[44] New hopes for cystic fibrosis treatments [J].

Coudert, Pascal ;

Daulhac-Terrail, Laurence .

ACTUALITES PHARMACEUTIQUES, 2021, 60 (604) :46-50

[45] Overweight and cystic fibrosis: An unexpected challenge [J].

Gabel, Megan E. ;

Fox, Claudia K. ;

Grimes, Rachel A. ;

Lowman, John D. ;

McDonald, Catherine M. ;

Stallings, Virginia A. ;

Michel, Suzanne H. .

PEDIATRIC PULMONOLOGY, 2022, 57 :S40-S49

[46] Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis [J].

Shiferaw, Dejene ;

Faruqi, Shoaib .

THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 :1029-1040

[47] Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor [J].

Singh, Sachinkumar B. ;

McLearn-Montz, Amanda J. ;

Milavetz, Francesca ;

Gates, Levi K. ;

Fox, Christopher ;

Murry, Logan T. ;

Sabus, Ashley ;

Porterfield, Harry S. ;

Fischer, Anthony J. .

PEDIATRIC PULMONOLOGY, 2019, 54 (08) :1200-1208

[48] Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist [J].

Lee, Saangyoung E. ;

Farzal, Zainab ;

Daniels, M. Leigh Anne ;

Thorp, Brian D. ;

Zanation, Adam M. ;

Senior, Brent A. ;

Ebert, Charles S., Jr. ;

Kimple, Adam J. .

AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2020, 34 (04) :573-580

[49] Year to year change in FEV1 in patients with cystic fibrosis and different-mutation classes [J].

De Boeck, K. ;

Zolin, A. .

JOURNAL OF CYSTIC FIBROSIS, 2017, 16 (02) :239-245

[50] Ivacaftor: Five-year outcomes in the West of Scotland cystic fibrosis population [J].

Al-Din, Yasmin ;

Dryden, Carol ;

MacGregor, Gordon ;

Young, David ;

Coelho, Cristina .

CLINICAL RESPIRATORY JOURNAL, 2023, 17 (05) :473-477

← 1 2 3 4 5 →